MNOVのチャート
MNOVの企業情報
| symbol | MNOV |
|---|---|
| 会社名 | Medicinova Inc （メディシノバ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 メディシノバ(MediciNova Inc.)は主に米国市場を中心とした疾患の治療のための小分子治療薬を取得・開発するバイオ製薬企業である。同社の主要製品はMN-166（ibudilast）、MN-001（tipelukast）、MN-221（bedoradrine）、MN-029（denibulin）等がある。MN-166は経口で、抗炎症薬および神経保護剤であり、進行性多発性硬化症、筋萎縮性側索硬化症、物質依存および中毒などの神経的疾患の治療薬を開発する。MN-001（tipelukast）は非アルコール性脂肪性肝炎と特発性肺線維症などの線維性疾患を治療する経口の低分子化合物である。MN-221は静脈内注入で喘息の急性増悪を治療する。MN-029固形腫瘍癌を治療する。 メディシノバは、米国のバイオ医薬品企業。多発性硬化症、薬物依存、非アルコ―ル性脂肪性肝炎（NASH）、肺線維症、神経因性疼痛薬、慢性閉塞性肺疾患（COPD）、筋萎縮性側索硬化症(ASL)、気管支喘息急性発作などに対する治療薬の開発、商業化に従事。本社はカリフォルニア州。 MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). |
| 本社所在地 | 4275 Executive Square Suite 300 La Jolla CA 92037 USA |
| 代表者氏名 | Jeffrey Himawan ジェフリー・ヒマワン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-373-1500 |
| 設立年月日 | 36770 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 9人 |
| url | www.medicinova.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mnov |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.23832 |
| 終値（lastsale） | 11.66 |
| 時価総額（marketcap） | 488309991.18 |
| 時価総額 | 時価総額（百万ドル） 431.77330 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 367.61052 |
| 当期純利益 | 当期純利益（百万ドル） -13.74516 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 MediciNova Inc. revenues was not reported. Net loss increased 32% to $7.7M. Higher net loss reflects Research and development and patents increase of 69% to $3M (expense) General and administrative increase of 25% to $5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.19. |
MNOVのテクニカル分析
MNOVのニュース
Alcohol Use Disorder Market is Expected to Expand at a Healthy Growth Rate by 2032, DelveInsight | Major Companies- Tonix Pharmaceuticals, Dupont, Medicinova, and Several Others 2022/10/11 13:08:35 OpenPR
DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference 2022/09/15 23:00:00 GlobeNewswire
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.
MediciNova to get US patent for MN-166 to treat brain cancer 2022/09/15 09:58:22 Seeking Alpha
MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…
MediciNova (NASDAQ: MNOV) Up Following Grant of Patent 2022/09/14 10:04:49 TipRanks
Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.
MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders 2022/09/14 08:56:13 Seeking Alpha
MediciNova (MNOV) said it will get a from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to…
Alcohol Use Disorder Market is Expected to Expand at a Healthy Growth Rate by 2032, DelveInsight | Major Companies- Tonix Pharmaceuticals, Dupont, Medicinova, and Several Others 2022/10/11 13:08:35 OpenPR
DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference 2022/09/15 23:00:00 GlobeNewswire
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.
MediciNova to get US patent for MN-166 to treat brain cancer 2022/09/15 09:58:22 Seeking Alpha
MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…
MediciNova (NASDAQ: MNOV) Up Following Grant of Patent 2022/09/14 10:04:49 TipRanks
Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.
MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders 2022/09/14 08:56:13 Seeking Alpha
MediciNova (MNOV) said it will get a from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to…
Alcohol Use Disorder Market is Expected to Expand at a Healthy Growth Rate by 2032, DelveInsight | Major Companies- Tonix Pharmaceuticals, Dupont, Medicinova, and Several Others 2022/10/11 13:08:35 OpenPR
DelveInsight''s "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alcohol Use Disorder Market Size and Share in the 7MM (i.e. the United
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference 2022/09/15 23:00:00 GlobeNewswire
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.
MediciNova to get US patent for MN-166 to treat brain cancer 2022/09/15 09:58:22 Seeking Alpha
MediciNova (MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.The new patent is expected to expire…
MediciNova (NASDAQ: MNOV) Up Following Grant of Patent 2022/09/14 10:04:49 TipRanks
Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application. This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, "We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S.